stoxline Quote Chart Rank Option Currency Glossary
  
Vaxxinity, Inc. (VAXX)
0.7175  0.029 (4.14%)    03-28 16:00
Open: 0.67
High: 0.73
Volume: 334,324
  
Pre. Close: 0.689
Low: 0.67
Market Cap: 91(M)
Technical analysis
2024-03-28 4:54:57 PM
Short term     
Mid term     
Targets 6-month :  1 1-year :  1.22
Resists First :  0.86 Second :  1.04
Pivot price 0.71
Supports First :  0.56 Second :  0.46
MAs MA(5) :  0.68 MA(20) :  0.72
MA(100) :  0.8 MA(250) :  1.5
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  37 D(3) :  33
RSI RSI(14): 49.9
52-week High :  3.09 Low :  0.56
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VAXX ] has closed below upper band by 48.2%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.73 - 0.73 0.73 - 0.74
Low: 0.66 - 0.67 0.67 - 0.67
Close: 0.71 - 0.72 0.72 - 0.72
Company Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Headline News

Thu, 28 Mar 2024
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - Yahoo Finance

Thu, 28 Mar 2024
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023 - InvestorPlace

Wed, 27 Mar 2024
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire

Thu, 14 Mar 2024
Vaxxinity Inc Motivates Team with Option Repricing Initiative - TipRanks.com - TipRanks

Fri, 08 Mar 2024
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology

Thu, 07 Mar 2024
Vaxxinity stock gains after data for Parkinson's disease drug - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 113 (M)
Shares Float 55 (M)
Held by Insiders 50.9 (%)
Held by Institutions 12.3 (%)
Shares Short 3,650 (K)
Shares Short P.Month 3,560 (K)
Stock Financials
EPS -0.53
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -46.8 %
Return on Equity (ttm) -127 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.58
Qtrly Earnings Growth 0 %
Operating Cash Flow -60 (M)
Levered Free Cash Flow -40 (M)
Stock Valuations
PE Ratio -1.36
PEG Ratio 0
Price to Book value 3.77
Price to Sales 0
Price to Cash Flow -1.36
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android